What is The Oncology Institute Inc's earnings per share (EPS)?

The Oncology Institute Inc (TOI) reported diluted earnings per share of $-0.54 for fiscal year 2025. This represents a 23.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

The Oncology Institute Inc Financials

TOI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows The Oncology Institute Inc (TOI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 31/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

The Oncology Institute Inc has an operating margin of -7.2%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 6/100, suggesting thin profitability after operating expenses. This is up from -15.3% the prior year.

Growth

The Oncology Institute Inc's revenue surged 27.8% year-over-year to $502.7M, reflecting rapid business expansion. This strong growth earns a score of 80/100.

Liquidity

The Oncology Institute Inc's current ratio of 1.59 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.

Cash Flow

While The Oncology Institute Inc generated -$24.6M in operating cash flow, capex of $3.2M consumed most of it, leaving -$27.8M in free cash flow. This results in a low score of 11/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

4/9

The Oncology Institute Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.41x

For every $1 of reported earnings, The Oncology Institute Inc generates $0.41 in operating cash flow (-$24.6M OCF vs -$60.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-3.2x

The Oncology Institute Inc earns $-3.2 in operating income for every $1 of interest expense (-$36.1M vs $11.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$502.7M

YoY+27.8%

5Y CAGR+21.8%

The Oncology Institute Inc generated $502.7M in revenue in fiscal year 2025. This represents an increase of 27.8% from the prior year.

EBITDA

-$29.1M

YoY+45.9%

The Oncology Institute Inc's EBITDA was -$29.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.9% from the prior year.

Net Income

-$60.6M

YoY+6.3%

The Oncology Institute Inc reported -$60.6M in net income in fiscal year 2025. This represents an increase of 6.3% from the prior year.

EPS (Diluted)

$-0.54

YoY+23.9%

The Oncology Institute Inc earned $-0.54 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.8M

YoY+8.4%

The Oncology Institute Inc generated -$27.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 8.4% from the prior year.

Cash & Debt

$33.6M

YoY-32.4%

5Y CAGR+106.2%

The Oncology Institute Inc held $33.6M in cash against $77.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

99M

YoY+30.5%

The Oncology Institute Inc had 99M shares outstanding in fiscal year 2025. This represents an increase of 30.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-7.2%

YoY+8.1pp

5Y CAGR-2.8pp

The Oncology Institute Inc's operating margin was -7.2% in fiscal year 2025, reflecting core business profitability. This is up 8.1 percentage points from the prior year.

Net Margin

-12.1%

YoY+4.4pp

5Y CAGR-4.4pp

The Oncology Institute Inc's net profit margin was -12.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.4 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$3.2M

YoY-15.5%

5Y CAGR+21.8%

The Oncology Institute Inc invested $3.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 15.5% from the prior year.

TOI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$502.7M+27.8%	$393.4M+21.3%	$324.2M+28.4%	$252.5M+24.4%	$203.0M+8.3%	$187.5M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$105.6M-2.1%	$107.8M-5.3%	$113.9M-4.9%	$119.7M+43.6%	$83.4M+99.0%	$41.9M
Operating Income	-$36.1M+40.0%	-$60.1M+21.9%	-$77.0M+6.0%	-$82.0M-78.7%	-$45.9M-459.4%	-$8.2M
Interest Expense	$11.3M+50.4%	$7.5M+10.6%	$6.8M+266.0%	-$4.1M-1375.6%	$320K-7.8%	$347K
Income Tax	-$131K	$0+100.0%	-$36K+85.2%	-$243K+63.8%	-$671K-36.1%	-$493K
Net Income	-$60.6M+6.3%	-$64.7M+22.2%	-$83.1M-54750.0%	$152K+101.4%	-$10.9M+23.7%	-$14.3M
EPS (Diluted)	$-0.54+23.9%	$-0.71+22.8%	$-0.92-338.1%	$-0.21-31.2%	$-0.16	$-0.24

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$142.0M+3.9%	$136.6M+14.0%	$119.8M+14.7%	$104.4M+4.1%	$100.3M+0.4%	$99.9M+1.3%	$98.6M+4.1%	$94.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$28.0M+11.0%	$25.3M-6.2%	$26.9M+6.0%	$25.4M+2.1%	$24.9M-6.7%	$26.6M-4.4%	$27.9M-2.0%	$28.5M
Operating Income	-$6.9M+14.2%	-$8.1M+28.2%	-$11.2M-13.1%	-$9.9M+16.9%	-$11.9M+13.9%	-$13.9M+15.3%	-$16.4M+8.9%	-$18.0M
Interest Expense	$1.9M-0.2%	$1.9M+2.7%	$1.9M-66.4%	$5.6M+376.9%	$1.2M-47.5%	$2.2M+5.1%	$2.1M+6.7%	$2.0M
Income Tax	$0	$0+100.0%	-$131K	$0	$0	$0	$0	$0
Net Income	-$7.5M+54.5%	-$16.5M+3.0%	-$17.0M+13.2%	-$19.6M-48.6%	-$13.2M+18.2%	-$16.1M-4.1%	-$15.5M+22.2%	-$19.9M
EPS (Diluted)	N/A	$-0.14+6.7%	$-0.15+28.6%	$-0.21	N/A	$-0.18-5.9%	$-0.17+22.7%	$-0.22

TOI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$164.7M-4.7%	$172.7M-17.5%	$209.2M-20.0%	$261.7M+28.6%	$203.4M+209.7%	$65.7M
Current Assets	$112.7M+0.3%	$112.4M-21.7%	$143.5M+10.0%	$130.4M-15.3%	$154.1M+418.4%	$29.7M
Cash & Equivalents	$33.6M-32.4%	$49.7M+48.3%	$33.5M+139.0%	$14.0M-87.8%	$115.2M+12697.1%	$900K
Inventory	$16.9M+68.1%	$10.0M-26.6%	$13.7M+47.7%	$9.3M+43.8%	$6.4M+47.9%	$4.4M
Accounts Receivable	$59.0M+22.1%	$48.3M+14.1%	$42.4M+6.4%	$39.8M+99.0%	$20.0M+16.7%	$17.1M
Goodwill	$7.2M0.0%	$7.2M0.0%	$7.2M-66.2%	$21.4M-19.6%	$26.6M+87.2%	$14.2M
Total Liabilities	$180.4M+6.7%	$169.1M+11.1%	$152.2M+9.9%	$138.5M+39.5%	$99.3M+164.1%	$37.6M
Current Liabilities	$71.0M+35.9%	$52.2M+50.1%	$34.8M+17.1%	$29.7M-0.3%	$29.8M+4.2%	$28.6M
Long-Term Debt	$77.4M-16.9%	$93.1M+7.3%	$86.8M+7.7%	$80.6M	$0-100.0%	$6.6M
Total Equity	-$15.7M-538.0%	$3.6M-93.7%	$57.0M-53.7%	$123.2M+18.3%	$104.2M+270.7%	$28.1M
Retained Earnings	-$271.4M-28.7%	-$210.8M-44.2%	-$146.2M-131.7%	-$63.1M+0.2%	-$63.2M-20.9%	-$52.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$164.7M+0.6%	$163.6M+2.4%	$159.8M-2.6%	$164.0M-5.0%	$172.7M-3.6%	$179.2M-0.2%	$179.6M-12.2%	$204.5M
Current Assets	$112.7M+2.4%	$110.1M+5.1%	$104.8M-1.9%	$106.8M-5.0%	$112.4M-3.4%	$116.4M+0.2%	$116.2M-17.7%	$141.2M
Cash & Equivalents	$33.6M+21.4%	$27.7M-8.7%	$30.3M-23.8%	$39.7M-20.0%	$49.7M+4.8%	$47.4M+30.1%	$36.4M+1.0%	$36.1M
Inventory	$16.9M-10.6%	$18.9M+19.6%	$15.8M+28.3%	$12.3M+22.6%	$10.0M-0.7%	$10.1M-10.7%	$11.3M-2.0%	$11.6M
Accounts Receivable	$59.0M-1.1%	$59.6M+7.2%	$55.7M+12.9%	$49.3M+2.0%	$48.3M-11.3%	$54.5M+0.9%	$54.0M-8.1%	$58.8M
Goodwill	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%	$7.2M
Total Liabilities	$180.4M+2.5%	$175.9M+4.2%	$168.8M+6.2%	$158.9M-6.0%	$169.1M+3.3%	$163.7M+8.8%	$150.4M-7.9%	$163.2M
Current Liabilities	$71.0M+8.2%	$65.6M+1.2%	$64.8M+8.8%	$59.5M+14.0%	$52.2M+11.7%	$46.8M+33.2%	$35.1M-23.3%	$45.8M
Long-Term Debt	$77.4M+1.6%	$76.2M+1.6%	$75.0M+1.5%	$73.9M-20.7%	$93.1M+1.7%	$91.5M+1.8%	$90.0M+1.8%	$88.4M
Total Equity	-$15.7M-28.1%	-$12.3M-36.6%	-$9.0M-277.3%	$5.1M+41.2%	$3.6M-76.8%	$15.5M-47.0%	$29.2M-29.3%	$41.3M
Retained Earnings	-$271.4M-2.8%	-$263.9M-6.7%	-$247.4M-7.4%	-$230.4M-9.3%	-$210.8M-6.7%	-$197.6M-8.9%	-$181.5M-9.3%	-$166.0M

TOI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$24.6M+7.4%	-$26.5M+26.9%	-$36.3M+41.2%	-$61.8M-89.0%	-$32.7M-6533.1%	$508K
Capital Expenditures	$3.2M-15.5%	$3.8M-17.0%	$4.6M-17.4%	$5.5M+94.2%	$2.8M+138.4%	$1.2M
Free Cash Flow	-$27.8M+8.4%	-$30.3M+25.8%	-$40.9M+39.2%	-$67.3M-89.4%	-$35.5M-5078.9%	-$686K
Investing Cash Flow	-$3.1M-106.7%	$46.2M-26.2%	$62.6M+147.6%	-$131.6M-982.9%	-$12.2M-37.4%	-$8.8M
Financing Cash Flow	$11.6M+431.0%	-$3.5M+49.0%	-$6.8M-107.4%	$92.2M-40.1%	$154.0M+1195.5%	$11.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$1.0M-88.7%	$9.0M	$0	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$3.2M+125.6%	-$12.6M-23.8%	-$10.2M-104.5%	-$5.0M-224.7%	$4.0M+388.4%	$819K+105.2%	-$15.7M+1.4%	-$15.9M
Capital Expenditures	$1.1M+75.5%	$604K-50.0%	$1.2M+268.3%	$328K-81.3%	$1.8M+536.6%	-$402K-122.0%	$1.8M+199.3%	$610K
Free Cash Flow	$2.2M+116.4%	-$13.2M-16.0%	-$11.4M-114.6%	-$5.3M-336.8%	$2.2M+438.4%	$417K+102.4%	-$17.5M-6.0%	-$16.5M
Investing Cash Flow	-$1.1M-75.5%	-$604K+50.0%	-$1.2M-498.0%	-$202K+88.5%	-$1.8M-116.9%	$10.4M-42.8%	$18.2M-6.3%	$19.4M
Financing Cash Flow	$3.7M-64.8%	$10.6M+440.0%	$2.0M+141.4%	-$4.7M-2790.2%	-$164K+32.5%	-$243K+88.7%	-$2.1M-128.9%	-$938K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0	N/A	N/A

TOI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-7.2%+8.1pp	-15.3%+8.5pp	-23.8%+8.7pp	-32.5%-9.9pp	-22.6%-18.2pp	-4.4%
Net Margin	-12.1%+4.4pp	-16.4%+9.2pp	-25.6%-25.7pp	0.1%+5.4pp	-5.4%+2.3pp	-7.6%
Return on Equity	N/A	-1801.7%-1656.0pp	-145.7%-145.8pp	0.1%+10.6pp	-10.5%+40.5pp	-51.0%
Return on Assets	-36.8%+0.6pp	-37.4%+2.3pp	-39.7%-39.8pp	0.1%+5.4pp	-5.4%+16.4pp	-21.8%
Current Ratio	1.59-0.6	2.15-2.0	4.12-0.3	4.39-0.8	5.17+4.1	1.04
Debt-to-Equity	-4.92-30.9	25.95+24.4	1.52+0.9	0.65+0.7	0.00-0.2	0.23
FCF Margin	-5.5%+2.2pp	-7.7%+4.9pp	-12.6%+14.0pp	-26.7%-9.2pp	-17.5%-17.1pp	-0.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-4.9%+1.0pp	-5.9%+3.5pp	-9.4%+0.1pp	-9.5%+2.4pp	-11.9%+2.0pp	-13.9%+2.7pp	-16.6%+2.4pp	-19.0%
Net Margin	-5.3%+6.8pp	-12.1%+2.1pp	-14.2%+4.6pp	-18.8%-5.6pp	-13.2%+3.0pp	-16.1%-0.4pp	-15.7%+5.3pp	-21.0%
Return on Equity	N/A	N/A	N/A	-386.4%-19.1pp	-367.3%-263.2pp	-104.1%-51.1pp	-53.0%-4.8pp	-48.2%
Return on Assets	-4.6%+5.5pp	-10.1%+0.5pp	-10.6%+1.3pp	-11.9%-4.3pp	-7.6%+1.4pp	-9.0%-0.4pp	-8.6%+1.1pp	-9.7%
Current Ratio	1.59-0.1	1.68+0.1	1.62-0.2	1.79-0.4	2.15-0.3	2.49-0.8	3.31+0.2	3.08
Debt-to-Equity	-4.92+1.3	-6.21+2.1	-8.35-22.9	14.58-11.4	25.95+20.0	5.91+2.8	3.08+0.9	2.14
FCF Margin	1.5%+11.2pp	-9.7%-0.2pp	-9.5%-4.4pp	-5.1%-7.3pp	2.2%+1.8pp	0.4%+18.2pp	-17.7%-0.3pp	-17.4%

Note: Shareholder equity is negative (-$15.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Joint Corp JYNT

$121.4M

DOCGO INC DCGO

$56.3M

Biote BTMD

$48.8M

Community Health Sys Inc CYH

$410.3M

Cross Ctry Healthcare Inc CCRN

$295.6M

Frequently Asked Questions

What is The Oncology Institute Inc's annual revenue?

The Oncology Institute Inc (TOI) reported $502.7M in total revenue for fiscal year 2025. This represents a 27.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is The Oncology Institute Inc's revenue growing?

The Oncology Institute Inc (TOI) revenue grew by 27.8% year-over-year, from $393.4M to $502.7M in fiscal year 2025.

Is The Oncology Institute Inc profitable?

No, The Oncology Institute Inc (TOI) reported a net income of -$60.6M in fiscal year 2025, with a net profit margin of -12.1%.

What is The Oncology Institute Inc's EBITDA?

The Oncology Institute Inc (TOI) had EBITDA of -$29.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does The Oncology Institute Inc have?

As of fiscal year 2025, The Oncology Institute Inc (TOI) had $33.6M in cash and equivalents against $77.4M in long-term debt.

What is The Oncology Institute Inc's operating margin?

The Oncology Institute Inc (TOI) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is The Oncology Institute Inc's net profit margin?

The Oncology Institute Inc (TOI) had a net profit margin of -12.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is The Oncology Institute Inc's free cash flow?

The Oncology Institute Inc (TOI) generated -$27.8M in free cash flow during fiscal year 2025. This represents a 8.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is The Oncology Institute Inc's operating cash flow?

The Oncology Institute Inc (TOI) generated -$24.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are The Oncology Institute Inc's total assets?

The Oncology Institute Inc (TOI) had $164.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are The Oncology Institute Inc's capital expenditures?

The Oncology Institute Inc (TOI) invested $3.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does The Oncology Institute Inc have outstanding?

The Oncology Institute Inc (TOI) had 99M shares outstanding as of fiscal year 2025.

What is The Oncology Institute Inc's current ratio?

The Oncology Institute Inc (TOI) had a current ratio of 1.59 as of fiscal year 2025, which is generally considered healthy.

What is The Oncology Institute Inc's debt-to-equity ratio?

The Oncology Institute Inc (TOI) had a debt-to-equity ratio of -4.92 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is The Oncology Institute Inc's return on assets (ROA)?

The Oncology Institute Inc (TOI) had a return on assets of -36.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is The Oncology Institute Inc's cash runway?

Based on fiscal year 2025 data, The Oncology Institute Inc (TOI) had $33.6M in cash against an annual operating cash burn of $24.6M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is The Oncology Institute Inc's debt-to-equity ratio negative or unusual?

The Oncology Institute Inc (TOI) has negative shareholder equity of -$15.7M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is The Oncology Institute Inc's Piotroski F-Score?

The Oncology Institute Inc (TOI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are The Oncology Institute Inc's earnings high quality?

The Oncology Institute Inc (TOI) has an earnings quality ratio of 0.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can The Oncology Institute Inc cover its interest payments?

The Oncology Institute Inc (TOI) has an interest coverage ratio of -3.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is The Oncology Institute Inc?

The Oncology Institute Inc (TOI) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.